A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
This is a continuation of application Ser. No. 09/538,337 filed on Mar. 29, 2000 which is a continuation of U.S. patent application Ser. No. 09/321,522 filed on May 27, 1999 now U.S. Pat. No. 6,303,607, which claims priority to U.S. patent application Ser. No. 60/099,804 filed on Sep. 10, 1998.
